Apogee Therapeutics

target reach ladder climb meet win beat competition
Biotech

Apogee data drive hype as threat to Lilly, Sanofi becomes clear

Analysts doubled their peak sales forecast to $5.2 billion in the belief zumilokibart will become the first-line treatment for most eczema patients.
Nick Paul Taylor Mar 23, 2026 9:00am
eczema atopic dermatitis Black African American patient skin of color

Apogee claims IL-13 antibody sets new eczema treatment standard

Jul 7, 2025 8:29am
parachute chutes and ladders

Sanofi finds new R&D head—Chutes & Ladders

Sep 1, 2023 9:30am
Wall Street stock exchange finance shares share price Nasdaq

Apogee, Sagimet overshoot IPO expectations as they reach Nasdaq

Jul 14, 2023 8:55am
water thaw

2 biotechs test icy IPO waters with $228M and $66M offerings

Jul 10, 2023 11:43am